ALTANA gets MHRA approval for Alvesco (Ciclesonide)

ALTANA AG has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom has granted ALTANA Pharma marketing approval for Alvesco (Ciclesonide), a lung-activated inhaled corticosteroid with novel release and distribution properties.

Alvesco is indicated as prophylactic treatment of persistent asthma in adults.

The United Kingdom is serving as the Reference Member State for the European Mutual Recognition Procedure that will be initiated to gain marketing approval for Alvesco in participating countries. This approval of Alvesco in the UK is another major milestone for ALTANA Pharma. Other approvals will follow, so that patients in many countries can benefit from Alvesco.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Healthcare workers unprepared for mpox outbreak due to knowledge gaps and vaccine inequity